🏛️ Verified NIH Record • Updated 2026-08-25

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (NCT06290141)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Sanofi

🩺 Plain-English Summary (8th-Grade Level)

The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (13 items) and avoid the listed exclusions (33 items).

Location: Alabama Neurology Associates- Site Number : 8400019 — Homewood, Alabama

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
  • Polyneuropathy of other causes, including but not limited to acute demyelinating polyneuropathies (eg, Guillain-Barré syndrome), hereditary demyelinating neuropathies, neuropathies secondary to infection or systemic disease, diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor neuropathy, polyneuropathy related to IgM monoclonal gammopathy, POEMS syndrome, lumbosacral radiculoplexus neuropathy.
  • Sensory CIDP, distal CIDP and focal CIDP variants.
  • Any other neurological or systemic disease that can cause symptoms and signs interfering with treatment or outcome assessments.
  • Poorly controlled diabetes
  • Serious infections requiring hospitalization within 30 days prior to Screening, any active infection requiring antimicrobial treatment during Screening, or presence of a condition that may predispose the participant to increased risk of infection (eg, medical history such as known immunodeficiency or history of recurrent infections).
  • Clinical diagnosis of Systemic Lupus Erythematosus (SLE) or family history of SLE. For a participant with an antinuclear antibody (ANA) titer ≥1:160 and a positive anti double-stranded DNA (anti-dsDNA) at Screening, SLE diagnosis must be ruled out prior to enrollment.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study. Specifically, history of any hypersensitivity reaction to riliprubart or its components or of a severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibody.
  • Any contraindication related to the administration of immunoglobulins (eg hypersensitivity, chronic kidney disease, thromboembolic diseases or recent thromboembolic event, known history of IgA deficiency at the time of Screening).
  • Any other clinically meaningful medical history or ongoing medical condition (as determined by the Investigator at Screening) that might impact the benefit-risk assessment, jeopardize the safety of the participant, or compromise the quality of the data collected in this study; or history or presence of other significant concomitant illness that would adversely affect participation in this study, per the Investigator's judgment.
  • Documented history of attempted suicide over the 6 months prior to the Screening visit, presence of suicidal ideation of category 4 or 5 on the C-SSRS during Screening, OR if in the Investigator's judgment, the participant is at risk for a suicide attempt.
  • Evidence of CIDP worsening within the 6 weeks following a prior vaccination that, in the opinion of the Investigator, constituted a relapse.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (135 Sites)

  • Alabama Neurology Associates- Site Number : 8400019 — Homewood, Alabama
  • Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014 — Scottsdale, Arizona
  • Keck School of Medicine of University of Southern California- Site Number : 8400002 — Los Angeles, California
  • University of California Irvine Medical Center- Site Number : 8400007 — Orange, California
  • IMMUNOe International Research Centers - Centennial- Site Number : 8400049 — Centennial, Colorado
  • Yale University School of Medicine- Site Number : 8400018 — New Haven, Connecticut
  • Nova Clinical Research - Bradenton- Site Number : 8400044 — Bradenton, Florida
  • Design Neuroscience Center- Site Number : 8400053 — Miami Lakes, Florida
  • AdventHealth Orlando- Site Number : 8400006 — Orlando, Florida
  • AdventHealth Site Number : 8400006 — Orlando, Florida
  • NorthShore University Health System - Glenbrook Hospital- Site Number : 8400024 — Glenview, Illinois
  • University of Kansas Medical Center- Site Number : 8400010 — Kansas City, Kansas
  • Ochsner Medical Center - Jefferson Highway- Site Number : 8400030 — New Orleans, Louisiana
  • Johns Hopkins Hospital- Site Number : 8400015 — Baltimore, Maryland
  • Massachusetts General Hospital- Site Number : 8400009 — Boston, Massachusetts
  • Henry Ford Hospital- Site Number : 8400025 — Detroit, Michigan
  • Michigan State University- Site Number : 8400038 — East Lansing, Michigan
  • Washington University School of Medicine - Siteman Cancer Center- Site Number : 8400037 — St Louis, Missouri
  • Profound Research- Site Number : 8400052 — Las Vegas, Nevada
  • Dent Neurologic Institute - Amherst- Site Number : 8400039 — Amherst, New York
  • Hospital for Special Surgery - Site Number : 8400041 — New York, New York
  • Columbia University Irving Medical Center- Site Number : 8400003 — New York, New York
  • Lenox Hill Hospital- Site Number : 8400051 — New York, New York
  • Raleigh Neurology Associates- Site Number : 8400043 — Raleigh, North Carolina
  • University of Cincinnati Medical Center- Site Number : 8400020 — Cincinnati, Ohio

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗